Synthetic Lethality Key Opinion Leader(KOL) Webinar

The webinar will feature a leading expert on synthetic lethality in DNA damage repair (DDR) deficient tumors, Zoltan Szallasi, M.D. During the webinar, Dr. Szallasi discusses a broad range of topics surrounding synthetic lethality, including a brief history of synthetic lethality in oncology, how synthetic lethality is being leveraged to successfully treat cancers with DDR deficiencies, the promising potential of LP-184’s synthetic lethality for DDR deficient tumors, and the potential to combine LP-184 with FDA approved agents to enhance LP-184’s anti-tumor potency.
About our Key Opinion Leader:
Zoltan Szallasi, M.D. - group leader of the Translational Cancer Genomics Department at the Danish Cancer Society Research Center, faculty at the Computational Health Informatics Program (CHIP), Assistant Professor of Pediatrics at Boston Children's Hospital, affiliated with Harvard Medical School
#Oncology #CancerResearch